KR20200072059A - A pharmaceutical composition containing Phellinuslinteus - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for treating mastitis diseases of livestock containing a Phellinus linteus extract. More specifically, the present invention relates to: a pharmaceutical composition having functions of preventing and treating diseases related to various breast inflammation and aging-induced mammary epithelial cell damage during milking of livestock such as cows and goats; and a novel use of the residue left after extracting an active component from Phellinus linteus or a medium for cultivation of Phellinus linteus.

Description

A pharmaceutical composition containing Phellinuslinteus for the treatment of livestock mastitis disease containing a situation mushroom extract

The present inventors conducted a continuous study in view of the need for the development of anti-inflammatory drugs derived from natural products as described above, and can use medicinal mushroom extract as an active ingredient in the pharmaceutical composition for preventing and treating mastitis disease in livestock. The present invention was completed by finding out that the active ingredient used in the pharmaceutical composition can be used, and the remaining medium for cultivation of edible mushrooms or medicinal mushrooms can be used as a feed additive.

Accordingly, an object of the present invention is to provide a pharmaceutical composition for the treatment of mastitis disease in livestock containing a situation mushroom extract. Another object of the present invention is to provide a new use of the medium for cultivation of the remaining residue or the situation mushrooms after extracting the active ingredient from the situation mushrooms.

The present invention relates to a pharmaceutical composition for the treatment of mastitis disease of livestock containing a situation mushroom extract, and more specifically, a situation containing a situation mushroom extract obtained by extracting the mycelium or dried product thereof as cow's milk, chlorine, etc. Extraction of active ingredients from pharmaceutical compositions and medicinal mushrooms that have the function of preventing and treating diseases related to various inflammations of breasts and damage to mammary epithelial cells due to aging caused by milking of livestock. It is about use.

The biggest problem among livestock inflammations is mastitis in milking cows. As a result of investigating the infection level of mastitis infected by various pathogenic microorganisms, it shows a high infection rate of about 8% for each division and 15% for each individual. , Milking cows have the highest incidence rate in milking cows, so that about 40% of diseases occurring in milking cows are mastitis (Son Bong-Hwan, 1997, oil and mastitis management, penbang)

Mastitis is a disease caused by a combination of complex factors, and there is no breakthrough treatment method or a way to suddenly eliminate mastitis, so it is necessary to prevent mastitis factors, measure their effectiveness, and proceed with confidence.

Mastitis is a disease that causes damage to breast tissue or impaired metabolic function due to various inflammatory factors, and environmental factors or breeding management conditions are directly involved as factors, but most occur in non-organic cows. It is also occurring in the unspecified wild cattle.

Once infected with mastitis, it is difficult to recover the normal amount of oil even after recovery, as well as the next organic phase, so you should focus on prevention. In general, mastitis includes acute mastitis, acute mastitis, chronic mastitis, clinical mastitis, and potential It can be divided into mastitis, among which the most problematic is acute mastitis, and in the case of chronic mastitis, its treatment is almost impossible.

In non-cows, the most isolated bacteria from mastitis are Streptomyces aureus, S epidermitidis, Streptococcus spp, etc., and Actinomyces pyogenes Actinomyces pyogenes, Peptococcus indolicus, and aerobic Gram-positive coliforms and E. coli are also involved. Other Mycoplasma mastitis and bovine parainfluenza 3 and Leptospira Leptospira), brucella, tuberculosis and other infectious diseases are causing mastitis (Jui-Seok Joo, 1997, cow mastitis and milking. Veterinary Science Research Institute of Rural Development Administration) That is, mastitis is caused by one special strain It can be said that it shows that the development of the therapeutic agent is very difficult because it is caused by a complex strain, but it is common to use an antibiotic with a very high titer in the treatment of mastitis. That is, Gentamicin, Norfloxacin, Enrofloxacin, etc. are used, and the problem of residual substances is seriously raised.

In general, when milking cows are infected with the disease and injections or ointments are used, the antibiotics contained in the drug are transferred to milk, so milked milk cannot be delivered, and the farmhouse's losses are enormous. In order to overcome this, there is a holiday period, and it is generally impossible to pay more than 5 days.

This not only directly affects the farmer's profits, but also has a huge influence on the milking cow's traits, and causes a decline in milking. The development of anti-inflammatory drugs derived from natural products, not antibiotics, in terms of the loss of farming and protection of milking cows. This is urgently required.

Conventional technology using the extract of circumcision mushrooms is a cosmetic composition for skin whitening (Korean Patent No. 2001-70531), a method for manufacturing whitening cosmetics (Korean Patent No. 1999-30419), hair growth composition (Korean Patent No. 2000) -53859), situation mushroom composition or its culture method (Korean Patent Publication No. 1996-13274, Korean Patent Publication No. 1997-27296, Korean Patent Publication No. 1999-33803).

However, these prior arts use a situational mushroom extract for cosmetics or the like and a method for cultivating a situational mushroom, which differs from the technical configuration of the present invention in which a situational mushroom extract is used as an animal medicine.

Accordingly, the present inventors have focused on the necessity of developing an anti-inflammatory agent derived from natural products as described above, and as a result of carrying out a continuous study, the medicinal mushroom extract can be used as an active ingredient of a pharmaceutical composition for preventing and treating mastitis disease in livestock, and The present invention was completed by finding out that the active ingredient used in the pharmaceutical composition of the extract can be used as a feed additive for the remaining residue or medium for cultivating situational mushrooms.

Accordingly, an object of the present invention is to provide a pharmaceutical composition for the treatment of mastitis disease in livestock containing a situation mushroom extract. Another object of the present invention is to provide a new use of the medium for cultivation of the remaining residue or the situation mushrooms after extracting the active ingredient from the situation mushrooms.

The pharmaceutical composition according to the present invention is manufactured by using natural substances with anti-inflammatory agents effective for damage to the mammary gland tissue caused by mastitis and shortening the life of the milking cow, which is the world's biggest problem in milking cows, and damage to dairy farmers by antibiotic injections, etc. It can be said that the effect is very excellent in that it can minimize.

In addition, by adding the residue of cultivation medium or extract for circumcision mushrooms to a special-purpose feed, it can be used to prevent diseases or to cure trauma quickly by increasing immunity, and also find its significance in terms of recycling of agricultural and marine waste.

The present invention is a pharmaceutical composition for treating mastitis disease of livestock containing 01-999% of situation mushroom extract as a means for achieving the above object, and extracting an active ingredient from situation mushrooms and feeding the remaining residue or medium for growing situation mushrooms It provides a method to be used as an additive.

Phellinus linteus extract used in the present invention is produced by extracting hot circumcision mushrooms, cultivated medicinal mushrooms, medicinal mushroom mycelium or dried products thereof by hot hot water extraction or ethanol extraction. After repeating the process of extracting hot water for 2 to 3 hours at a temperature of 105°C to 115°C for 2-3 times, concentration under reduced pressure can be used to obtain a mushroom extract containing polysaccharide components.

It has been reported so far that among the 17 species of basidiomycetes, mushrooms with significantly higher anticancer activity are clusters, shiitakes, tops, etc., but the anticancer effect of woody mud mushrooms (situation) has a much higher cancer tumor inhibition rate than other basidiomycetes 967 Up to %, the active effect of B lymphocytes and T lymphocytes that defeat cancer cells is usually 2 times that of mice, 25 times that of natural killer cells that kill bacteria that invade from outside, and 25 times that of phagocytic cells that eat bacteria. It is reported that the active effect is 2 times, the antibody production rate is increased 25 times, and the life is extended by 18 times (Pharmaceutical Newspaper, 1994 July 22). The situation mushroom extract used in the present invention is a drug according to a conventional method. A pharmaceutical composition having the function of preventing and treating diseases related to various inflammations of the breast and damage to mammary epithelial cells due to aging caused by milking livestock such as cows, goats, etc. by mixing with an appropriate excipient that is academically acceptable or diluted with a diluent Can be prepared, prepared with ointment for breast application containing 1-90% (w/w) of medicinal mushroom extract and pharmaceutically acceptable excipients, or 1-90% (w/v) of medicinal mushroom extract with pharmaceuticals It can be prepared as an injection for nipple insertion containing a scientifically acceptable diluent.

Examples of excipients and diluents suitable for pharmaceutical compositions according to the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, Erythritol, malitol, starch, acacia gum, alginate, gelatin, calcium phosphate,

Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate ), propylhydroxy benzoate, talc, magnesium stearylate, cetanol, stearyl alcohol, n-paraffin, sorbitan mono And sorbitnmono stearylate, polysorbate 60, methyl paraben, and propyl paraben.

The pharmaceutical composition according to the present invention may further include a filler, an anti-coagulant, a lubricant, a wetting agent, a spice, an emulsifier, a preservative, etc. The formulations can be formulated using methods well known in the art to provide sustained or delayed release, and the formulations may include suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, sterile external preparations, etc. It can be in the form.

The pharmaceutical composition according to the present invention is prepared as an injection for nipple insertion, and may be administered through various routes including oral, transdermal, subcutaneous, intravenous or intramuscular, and is contained as an active ingredient of the pharmaceutical composition according to the present invention The usual daily dose of mushroom extract is in the range of 001 to 002 ml/kg body weight, and can be administered once or in multiple doses.

However, it should be understood that the actual dosage of the active ingredient should be determined in light of various relevant factors such as the route of administration, weight, severity of symptoms, etc., therefore, the dosage does not limit the scope of the present invention in any way. .

In addition, in the present invention, cultivation of circumcision mushrooms, or preparations of medicinal mushroom extracts and drying of the remaining by-products can be powdered into 10 to 90 mesh to provide feed additives for mammals, fish, and birds. In the case of large animals, it can be used for calf, beef cattle, and milk cows. For pigs, it can be used for pigs or pigs for chickens, for chickens, for broilers, broilers, and for fish.

In addition, it can be used as a feed additive for other feeds, such as pet dogs, birds, hamsters, rabbits, etc., and can be added to feeds for ornamental fish to prevent contamination of the water tank and to enhance immunity of ornamental fish.

Hereinafter, the present invention will be specifically described through an example test example. However, these examples and test examples are intended to illustrate the present invention in more detail, and are not intended to limit the scope of the present invention.

<Example 1> (Preparation of a situational mushroom extract) After repeating the process of extracting a situational mushroom and a situational mushroom mycelium for 25 hours at a temperature of 110° C. for 3 hours, concentrated under reduced pressure to 700 mmHg to include a polysaccharide component. After obtaining the situation mushroom extract, the extract was filtered with 260 mesh and concentrated under reduced pressure to 700 mmHg at 60°C to adjust the sugar content with 25 Brix to prepare a situation mushroom extract.

<Example 2> (Preparation of ointment)

Purified situation mushroom extract prepared in Example 1 was filtered using a filter having a pore size of 35 μm, filtered purified situation mushroom extract 100 mg, 50 mg of cethanol, 50 mg of stearyl alcohol, 80 mg of liquid paraffin, propylene Ointment was prepared by mixing 150 mg of glycol, 20 mg of sorbitan monostearate, 20 mg of polysorbate 60, 10 mg of methylparaben, and 10 mg of propylparaben.

<Example 3> (Preparation of muscle injection)

Filtrate mushrooms prepared in Example 1 were filtered with a fiber filter layer filter using different membrane pore size filters of 3㎛, 10㎛, 045㎛ and 02㎛, and autoclaved at 121℃ for 30 minutes. After performing the mixture, the purified medicinal mushroom extract cooled to room temperature was mixed with physiological saline to prepare an intramuscular injection.

<Example 4> (Preparation of injection for nipple insertion)

Phellinus linteus extract prepared in Example 1, filtered to 02㎛, extract of Phellinus linteus extract 07ml, physiological saline 02ml, polyethylene glycol 005ml, Tween-80 (Tween-80) 05ml, mixed and injected into the nipple in the usual way Was prepared.

<Example 5> (Preparation of pet food)

In Example 1, after preparing the medicinal mushroom extract and drying the remaining residue, 005% (w/w) of the by-product, which was powdered with 46 mesh, was added to Nextop-Juno (dominant feed), which is a feed for pet dogs. To prepare a pet food.

<Test Example 1> (change in the number of somatic cells by ointment)

In order to test the therapeutic effect of the pharmaceutical composition according to the present invention against mastitis disease, the ointment prepared in Example 2 was applied to the breast of a milk cow with mastitis twice a day in the morning and evening over a period of 5 days and then milked The results of examining the number of somatic cells by collecting the crude oil are shown in Table 1, wherein the control means the number of somatic cells of the crude milk before applying the ointment.

<Test Example 2> (Change of somatic cell number by muscle injection)

In order to test the therapeutic effect of the pharmaceutical composition according to the present invention against mastitis disease, the intramuscular injection prepared in Example 3 was administered once per day to milking cows infected with mastitis in an amount of 002 ml/kg, and the muscles of the hips for a total of 5 days. The results of examining the somatic cell number by collecting the milked milk after injection into the body are shown in Table 2, wherein the control means the somatic cell number of the milked milk before injection of the injection.

<Test Example 3> (Change of the number of somatic cells by the injection for nipple insertion)

In order to test the therapeutic effect of the pharmaceutical composition according to the present invention against mastitis disease, the injection agent for nipple insertion prepared in Example 4 was put into a plastic syringe used as a syringe for the treatment of mastitis and inserted into the nipple once a day for 5 days. The result of examining the somatic cell number by collecting the milked milk after injection was shown in Table 3, wherein the control means the number of somatic cells of the milked milk before the injection of the injection.

<Test Example 4> (Effect to prevent disease of pet food for dogs)

In order to test the disease-preventing effect of the feed for pet dogs prepared in Example 5, after adding and preparing 005% (w/w) to a commercially available neck stop-juno feed, 5 pet dogs fed with the normal feed and Examples Table 4 shows the results of examining the changes in the weight gain and the content of immunoglobin in the blood of 5 pet dogs ingesting the pet dog food prepared in 5.

Therefore, the feed according to the present invention improves the immune system and makes it resistant to various diseases and stresses, thereby increasing the weight of the pet dog and increasing resistance to various diseases.

Claims (7)

Pharmaceutical composition for the treatment of mastitis disease in livestock containing a situation mushroom extract as an active ingredient. The pharmaceutical composition for treating mastitis disease in livestock according to claim 1, wherein the circumcision mushroom extract is prepared by extracting hot circumcision mushrooms, cultivated circumcision mushrooms, circumcision mushroom mycelium or dried products thereof at high temperature hot water or ethanol extraction. According to claim 1, Pharmaceutical composition for treating mastitis disease in livestock, characterized in that it contains 01 to 999% of the situation mushroom extract. According to claim 3, The pharmaceutical composition is a pharmaceutical composition for the treatment of mammary inflammation in cattle, characterized in that it is prepared as an ointment for breast application containing 1-90% of medicinal mushroom extract and a pharmaceutically acceptable excipient. According to claim 3, The pharmaceutical composition is a pharmaceutical composition for treating mastitis disease in livestock, characterized in that it is prepared as an injection for nipple insertion containing 1-90% of medicinal mushroom extract and a pharmaceutically acceptable diluent. Method for preparing a situational mushroom cultivation medium used for cultivation of situational mushrooms or a pharmaceutical composition according to any one of claims 1 to 5, and using the remaining by-products as a feed additive. The method according to claim 6, wherein the by-product is dried and then powdered into 10 to 90 mesh.